This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Hyperion Therapeutics Announces Presentation Of Long Term Data On Ammonia Control In Pediatric Patients Treated With RAVICTI(R) At The 12th International Congress Of Inborn Errors Of Metabolism And The Urea Cycle Disorder Satellite Symposium

SOUTH SAN FRANCISCO, Calif., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced several data presentations at the 12 th International Congress of Inborn Errors of Metabolism (ICIEM) and the satellite symposium on urea cycle disorders (UCDs) held in Barcelona, Spain. Among the presentations, the company highlighted long term data regarding ammonia control in pediatric patients with UCDs who were treated with RAVICTI® (glycerol phenylbutyrate) Oral Liquid. UCD patients lack enzymes or transporters necessary for the conversion of ammonia to urea and experience heightened levels of ammonia in the bloodstream. Left untreated, UCDs can result in neurological damage, coma, and/or death.

The long term, prospectively collected, data, which were presented by Susan Berry, M.D., Professor of Pediatrics and Division Director for Genetics and Metabolism in the Department of Pediatrics at the University of Minnesota, were pooled from two studies with RAVICTI which involved 49 pediatric UCD patients less than 18 years of age, including 23 patients ages 2 months through 5 years. During 12-months of treatment with RAVICTI, mean monthly ammonia levels ranged from 17.2 to 24.8 umol/L and remained below the upper limit of normal (35 umol/L). In addition, patients' physical growth and development were similar to the normal population, as determined by Z scores for height and weight being within one standard deviation of the normal age-matched population. During the 12-month pre-study period, 45% of patients reported 38 hyperammonemic crises whereas 25% experienced 17 crises during the 12 months of open-label RAVICTI dosing. Common adverse events reported were gastrointestinal and upper respiratory tract infections. Four patients did not complete the 12-month treatment period with RAVICTI.

Pooled analysis of data from two previously reported short term trials that independently demonstrated RAVICTI to be non-inferior to BUPHENYL® (sodium phenylbutyrate) (Lichter 2011, Smith 2013) were also presented. Among the 26 patients ages 2 months through 17 years enrolled in these two switchover studies, mean daily ammonia exposure assessed as 24-hour area under the curve was 872 vs. 627 µmol/L*h (p = 0.008) for BUPHENYL and RAVICTI respectively. The percentage of abnormal ammonia values on BUPHENYL and RAVICTI were 35% and 15% (p = 0.02), respectively. All patients switched from BUPHENYL to RAVICTI in a single step and adverse events reported by more than one patient on RAVICTI were abdominal pain and vomiting, which generally decreased and/or resolved with continued treatment.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs